Opinion|Videos|December 12, 2023
Managing Interstitial Lung Disease in Patients With HER2+ mCRC Receiving Trastuzumab Deruxtecan
Experts explore the management of interstitial lung disease in patients with colorectal cancer receiving treatment with trastuzumab deruxtecan and the consideration of liquid biopsies to assess HER2 status and adapt treatment strategies.
Advertisement
Episodes in this series
Advertisement
Related to this article
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Dirk Schadendorf, MD, reviewed final STARBOARD data for encorafenib, binimetinib, and pembrolizumab in first-line BRAF V600–mutant melanoma.
Matthew Lee, MD, shares his key takeaway from the first disclosure of BG-C477 data in advanced NSCLC.
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
3
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
4
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
5